The Class I Histone deacetylase inhibitor a potent Therapeutic target for treating glioblastoma, MGCD0103 is a novel inhibitor in the induction death of cancer cells

Epigenetic abnormality is one of the hallmark glioblastoma cancer cells. Histone deacetylase modification has an important role in chromatin condensation, which results in the initiation and progression of glioblastoma cancer cells. Selective-isotype HDAC inhibitors are promising anti-cancer agents that target specific HDAC enzymes and inhibition of proliferation of many cancer cells. Selective HDAC inhibitors isoform provides a high efficacy as chemotherapy in inhibiting cancer confirmation compared to non-selective HDAC inhibitors. Selective HDAC inhibitors suppress Class I HDAC1, HDAC2, HDAC3, and HDAC11.  HDAC class I inhibitors induce apoptosis, differentiation, autophagic death cells, and reactive oxygen species (ROS)- induced cell death and inhibit cell migration, invasion, and angiogenesis in cancer cells while the normal cells showed more resistance to HDAC class I inhibitors. MGCD0103, a benzamide histone deacetylase, has a potent anti-cancer therapy that is used in the treatment of many cancers cell lines, and it has been approved by FAD in the treatment of Hodgkin lymphoma (HL) cell lines. MGCD0103 has vigorous inhibitory activity against HDAC1 but also targets action HDCA2, HDAC3and HDAC11. Therefore, MGCD0103 has expected to be a promising anti-cancer drug for treating a different variety of human cancer cells